
A clinical trial evaluating the use of convalescent plasma in patients with mild to moderate COVID-19 symptoms has been halted because the treatment didn’t benefit them, according to the U.S. National Institutes of Health. Convalescent plasma (also called “survivor’s plasma”) is derived from the blood of patients who have already recovered from COVID-19. It’s thought… read on > read on >